Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722237 | 0.91 | POLB (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL4119316 | 0.86 | GPR119 (0.42) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL29132568 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL966486 | 0.83 | GPR119 (0.39) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL22273315 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL19210153 | 0.82 | GPR119 (0.45) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL3315259 | 0.81 | TDP1 (0.37) | ALDH1A1POLBGAAMGAMSI | |
| SCHEMBL3311175 | 0.81 | TDP1 (0.37) | ALDH1A1POLBGAAMGAMSI | |
| SCHEMBL4498700 | 0.81 | GPR119 (0.40) | ALDH1A1CYP3A4POLBGPR119TP53 | |
| SCHEMBL6269261 | 0.80 | MGAM (0.40) | ALDH1A1POLBSMN1; SMN2GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| CN-117550989-B | Preparation method of trans-2- (4-aminocyclohexyl) ethyl acetate hydrochloride | 泰州精英化成医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024064328-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-117550989-A | Preparation method of trans-2- (4-aminocyclohexyl) ethyl acetate hydrochloride | 泰州精英化成医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | REMISZEWSKI STACY W (US) | 2001-07-12 | — | — | US | disclosed |
| US-6211193-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| CN-1286690-A | Compounds useful for inhibition of farnesyl protein transferase | SCHERING CORP (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-0993459-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-19 | — | — | EP | disclosed |
| US-5877199-A | ALZHEIMER'S DISEASE; SEDATIVE | SANKYO COMPANY, LIMITED (JP) | 1999-03-02 | — | — | US | disclosed |
| WO-1998057955-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0804416-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY LIMITED (JP) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
| WO-1992012977-A1 | SUBSTITUTED INDOLES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-06 | — | — | WO | disclosed |
| US-5124332-A | Dopaminergic agents, hypotensive agents | WARNER-LAMBERT COMPANY (US) | 1992-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | OPRL1, OPRK1, NOP56 | ALDH1A1 2958/4885CYP3A4 1905/4885CYP2C19 2465/4885 |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | ALDH1A1 2958/4885CYP3A4 1905/4885CYP2C19 2465/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ALDH1A1 305/4885CYP3A4 921/4885CYP2C19 701/4885 |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | HCCS, FNTB, CBR1 | ALDH1A1 795/4885CYP3A4 883/4885CYP2C19 2924/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ALDH1A1 219/4885CYP3A4 1482/4885CYP2C19 3094/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | ALDH1A1 1136/4885CYP3A4 462/4885CYP2C19 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.